Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 176

1.

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ.

J Alzheimers Dis. 2012;31(2):335-41. doi: 10.3233/JAD-2012-120508.

PMID:
22531418
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K.

J Alzheimers Dis. 2010;21(3):1005-12. doi: 10.3233/JAD-2010-100573.

PMID:
20634579
[PubMed - indexed for MEDLINE]
3.

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ.

Arch Neurol. 2008 Aug;65(8):1031-8. doi: 10.1001/archneur.65.8.1031.

PMID:
18695053
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men.

Tong G, Castaneda L, Wang JS, Sverdlov O, Huang SP, Slemmon R, Gu H, Wong O, Li H, Berman RM, Smith C, Albright C, Dockens RC.

Clin Drug Investig. 2012 Nov;32(11):761-9. doi: 10.1007/s40261-012-0006-4.

PMID:
23018285
[PubMed - indexed for MEDLINE]
5.

Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].

Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL, Atack JR.

J Pharmacol Exp Ther. 2005 May;313(2):902-8. Epub 2005 Mar 2.

PMID:
15743924
[PubMed - indexed for MEDLINE]
Free Article
6.

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A.

Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14. Review.

PMID:
22468891
[PubMed - indexed for MEDLINE]
7.

Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses.

Lu Y, Riddell D, Hajos-Korcsok E, Bales K, Wood KM, Nolan CE, Robshaw AE, Zhang L, Leung L, Becker SL, Tseng E, Barricklow J, Miller EH, Osgood S, O'Neill BT, Brodney MA, Johnson DS, Pettersson M.

J Pharmacol Exp Ther. 2012 Aug;342(2):366-75. doi: 10.1124/jpet.112.192625. Epub 2012 May 4.

PMID:
22562771
[PubMed - indexed for MEDLINE]
Free Article
8.

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM.

Ann Neurol. 2009 Jul;66(1):48-54. doi: 10.1002/ana.21623.

PMID:
19360898
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. Review.

PMID:
22087836
[PubMed - indexed for MEDLINE]
10.

BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells.

Jämsä A, Belda O, Edlund M, Lindström E.

J Biomed Sci. 2011 Oct 21;18:76. doi: 10.1186/1423-0127-18-76.

PMID:
22018341
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC.

Clin Neuropharmacol. 2005 May-Jun;28(3):126-32.

PMID:
15965311
[PubMed - indexed for MEDLINE]
12.

γ-secretase binding sites in aged and Alzheimer's disease human cerebrum: the choroid plexus as a putative origin of CSF Aβ.

Liu F, Xue ZQ, Deng SH, Kun X, Luo XG, Patrylo PR, Rose GM, Cai H, Struble RG, Cai Y, Yan XX.

Eur J Neurosci. 2013 May;37(10):1714-25. doi: 10.1111/ejn.12159. Epub 2013 Feb 22. Erratum in: Eur J Neurosci. 2013 Jul;38(2):2340.

PMID:
23432732
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.

Borghys H, Jacobs T, Van Broeck B, Dillen L, Dhuyvetter D, Gijsen H, Mercken M.

J Alzheimers Dis. 2014;38(1):39-48. doi: 10.3233/JAD-130599.

PMID:
23948925
[PubMed - indexed for MEDLINE]
14.

Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.

Svedružić ZM, Popović K, Smoljan I, Sendula-Jengić V.

PLoS One. 2012;7(3):e32293. doi: 10.1371/journal.pone.0032293. Epub 2012 Mar 30.

PMID:
22479317
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group.

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

PMID:
23883379
[PubMed - indexed for MEDLINE]
Free Article
16.

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.

J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.

PMID:
22090477
[PubMed - indexed for MEDLINE]
Free Article
17.

Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects.

Hata S, Taniguchi M, Piao Y, Ikeuchi T, Fagan AM, Holtzman DM, Bateman R, Sohrabi HR, Martins RN, Gandy S, Urakami K, Suzuki T; Japanese Alzheimer's Disease Neuroimaging Initiative.

Mol Neurodegener. 2012 Apr 25;7:16.

PMID:
22534039
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

γ-Secretase modulator in Alzheimer's disease: shifting the end.

Xia W, Wong ST, Hanlon E, Morin P.

J Alzheimers Dis. 2012;31(4):685-96. doi: 10.3233/JAD-2012-120751. Review.

PMID:
22710916
[PubMed - indexed for MEDLINE]
19.

Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.

Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, Danner S, Reichwald J, Ammaturo D, Staab D, Stoeckli M, Rueeger H, Neumann U, Staufenbiel M.

J Pharmacol Exp Ther. 2008 Nov;327(2):411-24. doi: 10.1124/jpet.108.140327. Epub 2008 Aug 7.

PMID:
18687920
[PubMed - indexed for MEDLINE]
Free Article
20.

Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.

Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM.

J Pharmacol Exp Ther. 2005 Feb;312(2):635-43. Epub 2004 Sep 27.

PMID:
15452193
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk